The DOI matches its Crossref record; 914 of the 914 references it cites were found in a registry or an index.
Human prostate cancer risk factors
Open accessAbstract
Prostate cancer has the highest prevalence of any nonskin cancer in the human body, with similar likelihood of neoplastic foci found within the prostates of men around the world regardless of diet, occupation, lifestyle, or other factors. Essentially all men with circulating androgens will develop microscopic prostate cancer if they live long enough. This review is a contemporary and comprehensive, literature-based analysis of the putative risk factors for human prostate cancer, and the results were presented at a multidisciplinary consensus conference held in Crystal City, Virginia, in the fall of 2002. The objectives were to evaluate known environmental factors and mechanisms of prostatic carcinogenesis and to identify existing data gaps and future research needs. The review is divided into four sections, including 1) epidemiology (endogenous factors [family history, hormones, race, aging and oxidative stress] and exogenous factors [diet, environmental agents, occupation and other factors, including lifestyle factors]); 2) animal and cell culture models for prediction of human risk (rodent models, transgenic models, mouse reconstitution models, severe combined immunodeficiency syndrome mouse models, canine models, xenograft models, and cell culture models); 3) biomarkers in prostate cancer, most of which have been tested only as predictive factors for patient outcome after treatment rather than as risk factors; and 4) genotoxic and nongenotoxic mechanisms of carcinogenesis. The authors conclude that most of the data regarding risk relies, of necessity, on epidemiologic studies, but animal and cell culture models offer promise in confirming some important findings. The current understanding of biomarkers of disease and risk factors is limited. An understanding of the risk factors for prostate cancer has practical importance for public health research and policy, genetic and nutritional education and chemoprevention, and prevention strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in relation to smoking: 40 years' observations on male British doctors
Doll, R., Peto, R., Wheatley, K., Gray, R., & Sutherland, I. (1994) · BMJ · doi:10.1136/bmj.309.6959.901 · Cited by 5,932
Moll, R., Franke, W. W., Schiller, D. L., Geiger, B., & Krepler, R. (1982) · Cell · doi:10.1016/0092-8674(82)90400-7 · Cited by 5,247
Cloning of a novel receptor expressed in rat prostate and ovary.
Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., & Gustafsson, J. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5925 · Cited by 4,788
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Developmental effects of endocrine-disrupting chemicals in wildlife and humans.
Colborn, T., vom Saal, F. S., & Soto, A. M. (1993) · Environmental Health Perspectives · doi:10.1289/ehp.93101378 · Cited by 3,445
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
Vaux, D. L., Cory, S., & Adams, J. M. (1988) · Nature · doi:10.1038/335440a0 · Cited by 3,219
Oxidative Stress, Caloric Restriction, and Aging
Sohal, R. S., & Weindruch, R. (1996) · Science · doi:10.1126/science.273.5271.59 · Cited by 3,131
bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
Boise, L. H., González-García, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nuñez, G., & Thompson, C. B. (1993) · Cell · doi:10.1016/0092-8674(93)90508-n · Cited by 3,087
Research works printed but not linked: 898
- Oishi, 1995, Cancer Surv., 23, 267
- Parkin, 1992, IARC Sci Publ., 120, 45
- Doherty, 1996, Br J Hosp Med., 55, 104
- Morrison, 1995, Can J Public Health., 86, 274
- Dijkman, 1996, Eur Urol., 30, 281, 10.1159/000474185 · doi:10.1159/000474185
- Wingo, 1998, Cancer Epidemiol Biomarkers Prev., 7, 271
- Merrill, 1996, J Natl Cancer Inst., 88, 1683, 10.1093/jnci/88.22.1683 · doi:10.1093/jnci/88.22.1683
- Mettlin, 1996, Cancer., 77, 150, 10.1002/(SICI)1097-0142(19960101)77:1<150::AID-CNCR25>3.0.CO;2-3 · doi:10.1002/(sici)1097-0142(19960101)77:1<150::aid-cncr25>3.0.co;2-3
- Levy, 1993, CMAJ., 149, 617
- Smart, 1997, CA Cancer J Clin., 47, 134, 10.3322/canjclin.47.3.134 · doi:10.3322/canjclin.47.3.134
- Pienta, 1995, Urology., 45, 93, 10.1016/S0090-4295(95)96996-9 · doi:10.1016/s0090-4295(95)96996-9
- Dhom, 1983, J Cancer Res Clin Oncol., 106, 210, 10.1007/BF00402610 · doi:10.1007/bf00402610
- Polednak, 1997, Cancer., 79, 99, 10.1002/(SICI)1097-0142(19970101)79:1<99::AID-CNCR14>3.0.CO;2-1 · doi:10.1002/(sici)1097-0142(19970101)79:1<99::aid-cncr14>3.0.co;2-1
- Newman, 1996, Radiol Technol., 68, 39
- Bostwick, 1992, Cancer., 70, 291, 10.1002/1097-0142(19920701)70:1+<291::AID-CNCR2820701317>3.0.CO;2-4 · doi:10.1002/1097-0142(19920701)70:1+<291::aid-cncr2820701317>3.0.co;2-4
- Partin, 1994, Urology., 44, 646, 10.1016/S0090-4295(94)80197-5 · doi:10.1016/s0090-4295(94)80197-5
- Bostwick, 2000, Curr Urol Rep., 1, 65, 10.1007/s11934-000-0037-x · doi:10.1007/s11934-000-0037-x
- Bostwick, 1987, Cancer., 59, 788, 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I · doi:10.1002/1097-0142(19870215)59:4<788::aid-cncr2820590421>3.0.co;2-i
- Montironi, 1996, Eur Urol., 30, 133, 10.1159/000474162 · doi:10.1159/000474162
- Allam, 1996, Mod Pathol., 9, 742
- Qian, 1997, Hum Pathol., 28, 143, 10.1016/S0046-8177(97)90097-6 · doi:10.1016/s0046-8177(97)90097-6
- Feneley, 1997, Prostate Cancer Prostatic Dis., 1, 79, 10.1038/sj.pcan.4500210 · doi:10.1038/sj.pcan.4500210
- Sakr, 1997, Eur Urol., 32, 15
- Keetch, 1995, J Urol., 154, 347, 10.1016/S0022-5347(01)67044-7 · doi:10.1016/s0022-5347(01)67044-7
- Raviv, 1996, Acta Urol Belgium., 64, 11
- Rovner, 1997, J Urol., 158, 138, 10.1097/00005392-199707000-00042 · doi:10.1097/00005392-199707000-00042
- Davidson, 1995, J Urol., 154, 1295, 10.1016/S0022-5347(01)66840-X · doi:10.1016/s0022-5347(01)66840-x
- Shepherd, 1996, J Urol., 156, 460, 10.1016/S0022-5347(01)65881-6 · doi:10.1016/s0022-5347(01)65881-6
- Langer, 1996, J Urol., 155, 228, 10.1016/S0022-5347(01)66601-1 · doi:10.1016/s0022-5347(01)66601-1
- Bostwick, 1996, Eur Urol., 30, 145, 10.1159/000474164 · doi:10.1159/000474164
- Bostwick, 1996, Cancer., 78, 330, 10.1002/(SICI)1097-0142(19960715)78:2<330::AID-CNCR22>3.0.CO;2-W · doi:10.1002/(sici)1097-0142(19960715)78:2<330::aid-cncr22>3.0.co;2-w
- Ferguson, 1994, Urology., 44, 91, 10.1016/S0090-4295(94)80015-4 · doi:10.1016/s0090-4295(94)80015-4
- Aquilina, 1997, J Natl Cancer Inst., 89, 689, 10.1093/jnci/89.10.689 · doi:10.1093/jnci/89.10.689
- Colombel, 1993, Am J Pathol., 143, 390
- Goldstein, 1995, Hum Pathol., 26, 887, 10.1016/0046-8177(95)90012-8 · doi:10.1016/0046-8177(95)90012-8
- Saez, 1998, Mod Pathol., 11, 1193
- Papadopoulos, 2001, Clin Cancer Res., 7, 1533
- Kirschenbaum, 1999, Mol Urol., 3, 163
- Molberg, 1994, Am J Clin Pathol., 101, 266, 10.1093/ajcp/101.3.266 · doi:10.1093/ajcp/101.3.266
- Shah, 2001, Arch Pathol Lab Med., 125, 141, 10.5858/2001-125-0141-HAHCOS · doi:10.5858/2001-125-0141-hahcos
- Bostwick, 1995, Arch Pathol Lab Med., 119, 444
- Varma, 2002, Arch Pathol Lab Med., 126, 554, 10.5858/2002-126-0554-MCFTDO · doi:10.5858/2002-126-0554-mcftdo
- Egan, 1997, Am J Surg Pathol., 21, 931, 10.1097/00000478-199708000-00007 · doi:10.1097/00000478-199708000-00007
- Zhou, 2001, Am J Clin Pathol., 115, 39, 10.1309/2APJ-YKBD-97EH-67GW · doi:10.1309/2apj-ykbd-97eh-67gw
- Bonin, 1997, Cancer., 79, 75, 10.1002/(SICI)1097-0142(19970101)79:1<75::AID-CNCR11>3.0.CO;2-3 · doi:10.1002/(sici)1097-0142(19970101)79:1<75::aid-cncr11>3.0.co;2-3
- Ozcan, 2001, Eur Urol., 40, 308, 10.1159/000049791 · doi:10.1159/000049791
- D'Amico, 2001, J Urol., 165, 126, 10.1097/00005392-200101000-00031 · doi:10.1097/00005392-200101000-00031
- Nelson, 2002, Urology., 59, 740, 10.1016/S0090-4295(02)01654-0 · doi:10.1016/s0090-4295(02)01654-0
- O'Malley, 2002, Urology., 59, 85, 10.1016/S0090-4295(01)01486-8 · doi:10.1016/s0090-4295(01)01486-8
- Freedland, 2002, J Urol., 167, 516, 10.1016/S0022-5347(01)69076-1 · doi:10.1016/s0022-5347(01)69076-1
- Sebo, 2001, Cancer., 91, 2196, 10.1002/1097-0142(20010601)91:11<2196::AID-CNCR1249>3.0.CO;2-# · doi:10.1002/1097-0142(20010601)91:11<2196::aid-cncr1249>3.0.co;2-#
- Merrick, 2002, Cancer J., 8, 79, 10.1097/00130404-200201000-00014 · doi:10.1097/00130404-200201000-00014
- Bahnson, 1989, Prostate., 15, 149, 10.1002/pros.2990150208 · doi:10.1002/pros.2990150208
- Montironi, 1993, Virchows Arch A Pathol Anat Histopathol., 422, 185, 10.1007/BF01621801 · doi:10.1007/bf01621801
- Weidner, 1993, Am J Pathol., 143, 401
- Brawer, 1994, Cancer., 73, 678, 10.1002/1097-0142(19940201)73:3<678::AID-CNCR2820730329>3.0.CO;2-6 · doi:10.1002/1097-0142(19940201)73:3<678::aid-cncr2820730329>3.0.co;2-6
- Hall, 1994, Urology., 44, 869, 10.1016/S0090-4295(94)80173-8 · doi:10.1016/s0090-4295(94)80173-8
- Vesalainen, 1994, Anticancer Res., 14, 709
- Epstein, 2000, Urology., 56, 283, 10.1016/S0090-4295(00)00640-3 · doi:10.1016/s0090-4295(00)00640-3
- Silberman, 1997, Cancer., 79, 772, 10.1002/(SICI)1097-0142(19970215)79:4<772::AID-CNCR14>3.0.CO;2-X · doi:10.1002/(sici)1097-0142(19970215)79:4<772::aid-cncr14>3.0.co;2-x
- de la Taille, 2000, Am J Clin Pathol., 113, 555, 10.1309/02W2-KE50-PKEF-G2G4 · doi:10.1309/02w2-ke50-pkef-g2g4
- Stamey, 1999, JAMA., 281, 1395, 10.1001/jama.281.15.1395 · doi:10.1001/jama.281.15.1395
- van den Ouden, 1998, Urol Int., 60, 17, 10.1159/000030197 · doi:10.1159/000030197
- McNeal, 1996, Am J Surg Pathol., 20, 1351, 10.1097/00000478-199611000-00006 · doi:10.1097/00000478-199611000-00006
- Mehta, 2001, Clin Cancer Res., 7, 81
- Whittemore, 1995, Am J Epidemiol., 141, 732, 10.1093/oxfordjournals.aje.a117495 · doi:10.1093/oxfordjournals.aje.a117495
- Klein, 1998, Prostate Cancer Prostatic Dis., 1, 297, 10.1038/sj.pcan.4500257 · DOI
- Damber, 1998, Int J Cancer., 78, 293, 10.1002/(SICI)1097-0215(19981029)78:3<293::AID-IJC5>3.0.CO;2-Q · doi:10.1002/(sici)1097-0215(19981029)78:3<293::aid-ijc5>3.0.co;2-q
- Bratt, 1999, Eur J Cancer., 35, 272, 10.1016/S0959-8049(98)00358-X · doi:10.1016/s0959-8049(98)00358-x
- Cerhan, 1999, Cancer Epidemiol Biomarkers Prev., 8, 53
- Lightfoot, 2000, Ann Epidemiol., 10, 470, 10.1016/S1047-2797(00)00112-5 · doi:10.1016/s1047-2797(00)00112-5
- Kalish, 2000, Urology., 56, 803, 10.1016/S0090-4295(00)00780-9 · DOI
- Kotsis, 2002, J Urol., 167, 1659, 10.1016/S0022-5347(05)65173-7 · doi:10.1016/s0022-5347(05)65173-7
- Cotter, 2002, Prostate., 50, 216, 10.1002/pros.10051 · doi:10.1002/pros.10051
- Stone, 2003, Ethn Dis., 13, 233
- Gronberg, 1999, Cancer., 86, 477, 10.1002/(SICI)1097-0142(19990801)86:3<477::AID-CNCR16>3.0.CO;2-K · doi:10.1002/(sici)1097-0142(19990801)86:3<477::aid-cncr16>3.0.co;2-k
- Schuurman, 1999, Epidemiology., 10, 192, 10.1097/00001648-199903000-00020 · doi:10.1097/00001648-199903000-00020
- McLellan, 1995, CMAJ., 153, 895
- Staples, 2003, Cancer Causes Control., 14, 161, 10.1023/A:1023073203467 · doi:10.1023/a:1023073203467
- Matikainen, 1999, Clin Cancer Res., 5, 1275
- Thiessen, 1974, Cancer., 34, 1102, 10.1002/1097-0142(197410)34:4<1102::AID-CNCR2820340421>3.0.CO;2-5 · doi:10.1002/1097-0142(197410)34:4<1102::aid-cncr2820340421>3.0.co;2-5
- Anderson, 1992, J Natl Cancer Inst., 84, 1114, 10.1093/jnci/84.14.1114 · doi:10.1093/jnci/84.14.1114
- Andrieu, 1991, Eur J Cancer., 27, 244, 10.1016/0277-5379(91)90506-9 · doi:10.1016/0277-5379(91)90506-9
- Henderson, 1982, Cancer Res., 42, 3232
- Ghanadian, 1979, Br J Cancer., 39, 696, 10.1038/bjc.1979.122 · doi:10.1038/bjc.1979.122
- Vatten, 1997, Cancer Epidemiol Biomarkers Prev., 6, 967
- Nomura, 1996, Cancer Epidemiol Biomarkers Prev., 5, 621
- Guess, 1997, Cancer Epidemiol Biomarkers Prev., 6, 21
- Chang, 2001, Prostate., 46, 62, 10.1002/1097-0045(200101)46:1<62::AID-PROS1009>3.0.CO;2-V · doi:10.1002/1097-0045(200101)46:1<62::aid-pros1009>3.0.co;2-v
- Stattin, 2001, J Clin Endocrinol Metab., 86, 1341
- Ross, 1986, J Natl Cancer Inst., 76, 45
- Barrett-Connor, 1990, Cancer Res., 50, 169
- Jackson, 1981, Progr Clin Biol Res., 53, 111
- Modugno, 2001, Clin Cancer Res., 7, 3092
- Haenszel, 1968, J Natl Cancer Inst., 40, 43
- Locke, 1980, J Natl Cancer Inst., 65, 1149
- Stellman, 1994, Cancer., 73, 1270, 10.1002/1097-0142(19940215)73:4<1270::AID-CNCR2820730423>3.0.CO;2-Y · doi:10.1002/1097-0142(19940215)73:4<1270::aid-cncr2820730423>3.0.co;2-y
- Merrill, 2000, Urology., 55, 730, 10.1016/S0090-4295(99)00564-6 · doi:10.1016/s0090-4295(99)00564-6
- Abdalla, 1998, Semin Urol Oncol., 16, 207
- Asbell, 2000, J Natl Med Assoc., 92, 445
- Zhang, 2000, J Urol., 163, 131, 10.1016/S0022-5347(05)67988-8 · doi:10.1016/s0022-5347(05)67988-8
- Fowler, 2000, J Urol., 163, 1467, 10.1016/S0022-5347(05)67644-6 · doi:10.1016/s0022-5347(05)67644-6
- Wu, 2001, Cancer Epidemiol Biomarkers Prev., 10, 533
- Reichardt, 1995, Cancer Res., 55, 3973
- Platz, 1999, Cancer Epidemiol Biomarkers Prev., 8, 1107
- Winter, 2001, Urology., 58, 614, 10.1016/S0090-4295(01)01273-0 · doi:10.1016/s0090-4295(01)01273-0
- Ekman, 1999, Prostate., 39, 262, 10.1002/(SICI)1097-0045(19990601)39:4<262::AID-PROS6>3.0.CO;2-P · doi:10.1002/(sici)1097-0045(19990601)39:4<262::aid-pros6>3.0.co;2-p
- Corder, 1995, Cancer Epidemiol Biomarkers Prev., 4, 655
- Yamada, 2001, Int J Cancer., 92, 683, 10.1002/1097-0215(20010601)92:5<683::AID-IJC1255>3.0.CO;2-4 · doi:10.1002/1097-0215(20010601)92:5<683::aid-ijc1255>3.0.co;2-4
- Leadon, 1990, Health Phys., 59, 15, 10.1097/00004032-199007000-00001 · doi:10.1097/00004032-199007000-00001
- Statland, 1992, Clin Chem., 38, 1587
- Palmiter, 1987, Experientia., 52, 63
- Yu, 1994, Cancer., 73, 596, 10.1002/1097-0142(19940201)73:3<596::AID-CNCR2820730316>3.0.CO;2-N · doi:10.1002/1097-0142(19940201)73:3<596::aid-cncr2820730316>3.0.co;2-n
- Hietanen, 1994, Eur J Clin Nutr., 48, 575
- Hietanen, 1991, Carcinogenesis., 12, 591, 10.1093/carcin/12.4.591 · doi:10.1093/carcin/12.4.591
- Clark, 1996, JAMA., 276, 1957, 10.1001/jama.1996.03540240035027 · DOI · Paper page
- Han, 1995, Carcinogenesis., 16, 951, 10.1093/carcin/16.4.951 · doi:10.1093/carcin/16.4.951
- Schuurman, 1999, Cancer., 86, 1019, 10.1002/(SICI)1097-0142(19990915)86:6<1019::AID-CNCR18>3.0.CO;2-H · doi:10.1002/(sici)1097-0142(19990915)86:6<1019::aid-cncr18>3.0.co;2-h
- Berg, 1975, Cancer Res., 35, 3345
- Blair, 1978, J Natl Cancer Inst., 61, 1379
- Ohno, 1988, Cancer Res., 48, 1331
- Mettlin, 1989, Cancer., 64, 605, 10.1002/1097-0142(19890801)64:3<605::AID-CNCR2820640307>3.0.CO;2-I · doi:10.1002/1097-0142(19890801)64:3<605::aid-cncr2820640307>3.0.co;2-i
- Hayes, 1999, Cancer Epidemiol Biomarkers Prev., 8, 25
- Graham, 1983, J Natl Cancer Inst., 70, 687
- Ross, 1987, J Natl Cancer Inst., 78, 869
- Severson, 1989, Cancer Res., 49, 1857
- Mills, 1989, Cancer., 64, 598, 10.1002/1097-0142(19890801)64:3<598::AID-CNCR2820640306>3.0.CO;2-6 · doi:10.1002/1097-0142(19890801)64:3<598::aid-cncr2820640306>3.0.co;2-6
- Hirayama, 1979, Natl Cancer Inst Monogr., 53, 149
- Hsing, 1990, Cancer Res., 50, 6836
- De Stefani, 2000, Cancer Epidemiol Biomarkers Prev., 9, 335
- Harvei, 1997, Int J Cancer., 71, 545, 10.1002/(SICI)1097-0215(19970516)71:4<545::AID-IJC7>3.0.CO;2-U · doi:10.1002/(sici)1097-0215(19970516)71:4<545::aid-ijc7>3.0.co;2-u
- Bishop, 1988, Immunogenetics., 28, 184, 10.1007/BF00375858 · doi:10.1007/bf00375858
- Sporn, 1984, J Natl Cancer Inst., 73, 1381
- Kummet, 1983, Semin Oncol., 10, 281
- Olsen, 1996, Ugeskr Laeger., 158, 3171
- Kolonel, 1987, Cancer Res., 47, 2982
- Ellison, 1998, Chron Dis Can., 19, 1
- Paganini-Hill, 1987, J Natl Cancer Inst., 79, 443
- Hayes, 1988, Cancer., 62, 2021, 10.1002/1097-0142(19881101)62:9<2021::AID-CNCR2820620925>3.0.CO;2-R · doi:10.1002/1097-0142(19881101)62:9<2021::aid-cncr2820620925>3.0.co;2-r
- Reichman, 1990, Cancer Res., 50, 2311
- Wald, 1986, Br J Cancer., 54, 957, 10.1038/bjc.1986.267 · doi:10.1038/bjc.1986.267
- Nomura, 1997, Cancer Epidemiol Biomarkers Prev., 6, 487
- Cook, 1999, Cancer., 86, 1783, 10.1002/(SICI)1097-0142(19991101)86:9<1783::AID-CNCR21>3.0.CO;2-N · DOI
- Lu, 2001, Cancer Epidemiol Biomarkers Prev., 10, 749
- Hirayama, 1986, Gan No Rinsho., 32, 610
- Clinton, 1999, Cancer., 86, 1629, 10.1002/(SICI)1097-0142(19991101)86:9<1629::AID-CNCR1>3.0.CO;2-4 · doi:10.1002/(sici)1097-0142(19991101)86:9<1629::aid-cncr1>3.0.co;2-4
- Eichholzer, 1999, Prostate., 38, 189, 10.1002/(SICI)1097-0045(19990215)38:3<189::AID-PROS3>3.0.CO;2-N · doi:10.1002/(sici)1097-0045(19990215)38:3<189::aid-pros3>3.0.co;2-n
- Schwartz, 1990, Anticancer Res., 10, 1307
- Corder, 1993, Cancer Epidemiol Biomarkers Prev., 2, 467
- Peehl, 1999, Eur Urol., 35, 392, 10.1159/000019914 · doi:10.1159/000019914
- Suzuki, 2003, Int J Urol., 10, 261, 10.1046/j.1442-2042.2003.00617.x · doi:10.1046/j.1442-2042.2003.00617.x
- Schwartz, 1998, Cancer Epidemiol Biomarkers Prev., 7, 391
- Gann, 1996, Cancer Epidemiol Biomarkers Prev., 5, 121
- Schwartz, 1994, Anticancer Res., 14, 1077
- Chan, 1999, Cancer Epidemiol Biomarkers Prev., 8, 893
- Liang, 1999, Prostate., 40, 200, 10.1002/(SICI)1097-0045(19990801)40:3<200::AID-PROS8>3.0.CO;2-3 · doi:10.1002/(sici)1097-0045(19990801)40:3<200::aid-pros8>3.0.co;2-3
- Feustel, 1986, Prostate., 8, 75, 10.1002/pros.2990080109 · doi:10.1002/pros.2990080109
- Leake, 1984, Acta Endocrinol (Copenhagen)., 105, 281, 10.1530/acta.0.1050281 · doi:10.1530/acta.0.1050281
- Whelan, 1983, Br J Urol., 55, 525, 10.1111/j.1464-410X.1983.tb03362.x · doi:10.1111/j.1464-410x.1983.tb03362.x
- Chirulescu, 1987, Med Interne., 25, 257
- Ogunlewe, 1989, Cancer., 63, 1388, 10.1002/1097-0142(19890401)63:7<1388::AID-CNCR2820630725>3.0.CO;2-M · doi:10.1002/1097-0142(19890401)63:7<1388::aid-cncr2820630725>3.0.co;2-m
- Lekili, 1991, Int Urol Nephrol., 23, 151, 10.1007/BF02549712 · doi:10.1007/bf02549712
- McCallum, 1988, Br J Urol., 62, 565, 10.1111/j.1464-410X.1988.tb04427.x · doi:10.1111/j.1464-410x.1988.tb04427.x
- Feustel, 1989, Urol Res., 17, 41
- Tvedt, 1989, Prostate., 15, 41, 10.1002/pros.2990150105 · doi:10.1002/pros.2990150105
- Elghany, 1990, Epidemiology., 1, 107, 10.1097/00001648-199003000-00005 · doi:10.1097/00001648-199003000-00005
- Goodman, 2001, Cancer Epidemiol Biomarkers Prev., 10, 1069
- Nomura, 2000, Cancer Epidemiol Biomarkers Prev., 9, 883
- Grant, 1999, Altern Med Rev., 4, 162
- Rodriguez, 2003, Cancer Epidemiol Biomarkers Prev., 12, 597
- Balaji, 2001, Prostate., 48, 265, 10.1002/pros.1106 · doi:10.1002/pros.1106
- Sung, 1999, Cancer., 86, 484, 10.1002/(SICI)1097-0142(19990801)86:3<484::AID-CNCR17>3.0.CO;2-P · doi:10.1002/(sici)1097-0142(19990801)86:3<484::aid-cncr17>3.0.co;2-p
- Hsieh, 1999, Int J Cancer., 80, 699, 10.1002/(SICI)1097-0215(19990301)80:5<699::AID-IJC12>3.0.CO;2-7 · doi:10.1002/(sici)1097-0215(19990301)80:5<699::aid-ijc12>3.0.co;2-7
- van der Gulden, 1994, Br J Urol., 73, 382, 10.1111/j.1464-410X.1994.tb07601.x · doi:10.1111/j.1464-410x.1994.tb07601.x
- Kolonel, 1977, Lancet., 2, 566, 10.1016/S0140-6736(77)90714-0 · doi:10.1016/s0140-6736(77)90714-0
- Schuman, 1977, Cancer Treat Rep., 61, 181
- Niijima, 1980, Scand J Urol Nephrol., 55, 177
- Newell, 1998, Vet Radiol Ultrasound., 39, 332, 10.1111/j.1740-8261.1998.tb01616.x · doi:10.1111/j.1740-8261.1998.tb01616.x
- Talamini, 1993, Prev Med., 22, 400, 10.1006/pmed.1993.1033 · doi:10.1006/pmed.1993.1033
- Hayes, 1994, Cancer Causes Control., 5, 221, 10.1007/BF01830240 · doi:10.1007/bf01830240
- Lumey, 1997, Prostate., 33, 195, 10.1002/(SICI)1097-0045(19971101)33:3<195::AID-PROS8>3.0.CO;2-I · doi:10.1002/(sici)1097-0045(19971101)33:3<195::aid-pros8>3.0.co;2-i
- Giles, 2001, Ann Oncol., 12, 761, 10.1023/A:1011131105617 · doi:10.1023/a:1011131105617
- Plaskon, 2003, Cancer Epidemiol Biomarkers Prev., 12, 604
- Whittemore, 1985, J Natl Cancer Inst., 74, 43
- Carstensen, 1987, J Epidemiol Commun Health., 41, 166, 10.1136/jech.41.2.166 · DOI
- Giovannucci, 1999, Cancer Epidemiol Biomarkers Prev., 8, 277
- Colditz, 1996, Cancer Causes Control., 7, 560, 10.1007/BF00051890 · doi:10.1007/bf00051890
- Yu, 1997, Cancer Detect Prev., 21, 497
- Verhoeven, 1996, Cancer Epidemiol Biomarkers Prev., 5, 733
- Schuurman, 1998, Cancer Epidemiol Biomarkers Prev., 7, 673
- Kolonel, 2000, Cancer Epidemiol Biomarkers Prev., 9, 795
- Lee, 2003, Cancer Epidemiol Biomarkers Prev., 12, 665
- Gann, 1999, Cancer Res., 59, 1225
- Clinton, 1996, Cancer Epidemiol Biomarkers Prev., 5, 823
- Imaida, 2001, Carcinogenesis., 22, 467, 10.1093/carcin/22.3.467 · doi:10.1093/carcin/22.3.467
- Watson, 1995, Environ Health Perspect., 103, 41
- Soto, 1995, Environ Health Perspect., 103, 113
- Dees, 1997, Environ Health Perspect., 105, 625
- Adlercreutz, 1995, J Nutr., 125, 757s
- Telang, 1997, Proc Soc Exp Biol Med., 216, 246, 10.3181/00379727-216-44174 · doi:10.3181/00379727-216-44174
200 of 898 shown
Cited by
Epidemiology of Prostate Cancer
Rawla, P. (2019) · World Journal of Oncology · doi:10.14740/wjon1191 · Cited by 2,776
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 938
Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies
Hormones, E. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm323 · Cited by 786
Tang, W.-Y., Morey, L. M., Cheung, Y. Y., Birch, L., Prins, G. S., & Ho, S.-M. (2012) · Endocrinology · doi:10.1210/en.2011-1308 · Cited by 164
Self-citationBarrington, W. E., Schenk, J. M., Etzioni, R., Arnold, K. B., Neuhouser, M. L., Thompson, I. M., Lucia, M. S., & Kristal, A. R. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0513 · Cited by 107
Role of chemokines and chemokine receptors in prostate cancer development and progression.
Singh, R. K., Sudhakar, A., & Lokeshwar, B. L. (2010) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000030 · Cited by 45
Takahashi, R. H., Grigliatti, T. A., Reid, R. E., & Riggs, K. W. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.150995 · Cited by 21
Huang, M., Chen, L., Ma, X., & Xu, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03542-8 · Cited by 9
“The development of PCa is influenced by a complex inter-play of genetic, environmental, and lifestyle factors [4, 5].”
Background
Metadata
- Authors
- Bostwick, D. G., Burke, H. B., Djakiew, D., Euling, S., Ho, S.-M., Landolph, J., Morrison, H., Sonawane, B., Shifflett, T., Waters, D. J., & Timms, B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2004
- Volume
- 101
- Issue
- S10
- Pages
- 2371-2490
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2121518362
- Cited by
- 650
- References
- 914
- FWCI
- 18.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4261 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.